Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Korro Bio Completes $116M Series B Financing To Expand The Frontier Of Genetic Medicine Through Its Pipeline Of Rna Editing Programs
Korro Bio Completes $116M Series B Financing To Expand The Frontier Of Genetic Medicine Through Its Pipeline Of Rna Editing Programs
Company Info
Company news
Tue, 07 Jan 2025 08:00:00 GMT
Korro Bio CEO to Present RNA Editing Breakthroughs at JP Morgan Healthcare Conference - StockTitan
Tue, 28 Feb 2023 08:00:00 GMT
Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer - Business Wire
Thu, 21 Nov 2024 08:00:00 GMT
Korro Bio CEO to Present at Major Healthcare Conferences in December - StockTitan
Sat, 20 Jul 2024 07:00:00 GMT
KRRO Stock Price and Chart — NASDAQ:KRRO - TradingView
Mon, 13 Jan 2025 13:26:34 GMT
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update - The Manila Times
Mon, 16 Sep 2024 07:00:00 GMT
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates - StockTitan
Thu, 10 Sep 2020 07:00:00 GMT
Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics - Business Wire
Mon, 07 Oct 2019 07:00:00 GMT
Korro Bio Launched to Advance Groundbreaking New Approach to Nucleic Acid Editing - Business Wire
Mon, 13 Jan 2025 13:00:00 GMT
Korro Bio Launches First Clinical Trial for AATD Treatment KRRO-110, Marks Clinical Stage Milestone - StockTitan
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.